<DOC>
	<DOCNO>NCT02558751</DOCNO>
	<brief_summary>The investigator hypothesize vaccination either 23-valent pneumococcal polysaccharide vaccine ( PPV23 ) alone 13-valent pneumococcal conjugate vaccine ( PCV 13 ) follow PPV23 result similar antibody levels/functional activity induce similar pneumococcal polysaccharide ( PPS ) -specific B cell response HIV-positive individual &gt; 50 year age HIV-negative person &gt; 50 year age . The investigator immunize study group HIV+ person &gt; 50 control ( HIV negative &gt; 50 year ) PCV13 follow PPV23 HIV+ &gt; 50 PPV23 alone . The investigator examine immune response PPS23F PPS14 quantitative qualitative level use ELISA opsonophagocytic assay ( OPA ) . To test hypothesis level antigen specific B cell identify PPS comparable PPV23 PCV13 vaccine recipient . Pre- post-immunization peripheral blood sample obtain . Extensive B cell phenotype analysis use fluorescent antibody use characterize PPS-labeled B cell . Specific phenotype correlate antibody level OPA compare historic population immunize PPV .</brief_summary>
	<brief_title>Pneumonia Vaccine Aging HIV Positive Individuals</brief_title>
	<detailed_description>All potential study candidate ask fill questionnaire concern medical history medication . This survey determine eligibility . If eligible , part experimental protocol HIV positive participant agree randomized PPV23 alone versus PCV13 follow 8 week later PPV23 immunization 3 5 blood draw around time immunization . The HIV negative control population agree immunization PCV13 follow 8 week later PPV23 , standard care population , 5 blood draw around time immunization . The investigator compare effect single dose pneumococcal polysaccharide vaccination versus PCV13 follow PPV23 vaccination HIV positive adult . Prior 2012 , standard care HIV positive adult include vaccination PPV23 . In 2012 , recommendation change recommended HIV positive adult vaccinate PCV13 follow least 8 week later PPV23 . The benefit vaccination protocol PPV23 alone HIV positive adult &gt; 50 year age however study . As part study , HIV positive adult &gt; 50 year age CD4 count &gt; 200 due pneumococcal vaccination standard care , ask participate study . Those agree eligible participate randomly assign receive PCV13 follow least 8 week later PPV23 receive single vaccination PPV23 . As standard care , individual due pneumococcal vaccine eligible study receive PCV13 follow PPV23 . The HIV positive volunteer ( n=37 ) agree ( experimental part protocol ) : 1 . Be randomize either vaccination PCV13 follow PPV23 OR PPV23 alone . 2 . Donate blood specimens 3-5 different time : PPV23 group : day 0 , day vaccination : 2 mL , day 7 , 40 mL day 28-42 one time sample 2 mL PCV13/PPV23 group : day 0 , day vaccination PCV13 : 2 mL , day 7 , 40 mL day 56 , day PPPV23 , 2 mL , day 63 40 mL sample finally day 90 one time sample 2 mL . 3 . Have blood sample subject antibody analysis ( concentration functional activity ) PPS-specific B cell phenotype tumor necrosis factor receptor ( TNFR ) . The HIV negative control study ( n=14 ) agree participate vaccinate PCV13 follow PPV23.This NOT vaccine regime recommend healthy adult NOT contraindicate . Thus part experimental procedure individual : 1 . Receive FDA approve PCV13 PPV23 2 . Blood sample obtain day 0 , day vaccination PCV13 : 2 mL , day 7 , 40 mL day 56 , day PPPV23 , 2 mL , day 63 40 mL sample finally day 90 one time sample 2 mL . 3 . Blood sample analyze antibody concentration , functional activity PPS-specific B cell phenotype TNFR . In summary , investigator study 3 population , 50-65 year age : Group 1 : HIV positive CD4 &gt; 200 vaccinate PPV23 Group 2 : HIV positive CD4 &gt; 200 vaccinate PCV13 follow 8 week later PPV23 Group 3 : HIV negative vaccinate PCV13/PPV23 .</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>HIV negative : never immunize PCV13 HIV positive : need pneumococcal vaccination per standard care steroid use immunosuppressive agent ; pregnancy incapable complete consent form</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>pneumococcal conjugate vaccine</keyword>
	<keyword>age HIV</keyword>
</DOC>